Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 3591 entries
Sorted by: Best Match Show Resources per page
Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline.

A & A case reports

Bowler M, Nethercott DR.
PMID: 25611153
A A Case Rep. 2014 Feb 01;2(3):28-30. doi: 10.1097/ACC.0b013e3182a526fa.

We report the case of a 52-year-old man with a combined liraglutide and amitriptyline overdose who presented with a seizure and then pulseless electrical activity cardiac arrest. This is the largest reported overdose of liraglutide (36 mg), a novel...

Cite
Bowler M, Nethercott DR. Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A A Case Rep. 2014;2(3):28-30doi: 10.1097/ACC.0b013e3182a526fa.
Bowler, M., & Nethercott, D. R. (2014). Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A & A case reports, 2(3), 28-30. https://doi.org/10.1097/ACC.0b013e3182a526fa
Bowler, Matthew, and Nethercott, Daniel Robert. "Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline." A & A case reports vol. 2,3 (2014): 28-30. doi: https://doi.org/10.1097/ACC.0b013e3182a526fa
Bowler M, Nethercott DR. Two lessons from the empiric management of a combined overdose of liraglutide and amitriptyline. A A Case Rep. 2014 Feb 01;2(3):28-30. doi: 10.1097/ACC.0b013e3182a526fa. PMID: 25611153.
Copy Download .nbib Format: NLM
Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy.

Case reports in oncological medicine

Zyczynski LE, McHugh JB, Gribbin TE, Schuetze SM.
PMID: 26266067
Case Rep Oncol Med. 2015;2015:107479. doi: 10.1155/2015/107479. Epub 2015 Jul 22.

A 69-year-old woman was diagnosed with alveolar rhabdomyosarcoma (ARMS) of the nasopharynx. She has a history of catastrophic thromboembolic event in the abdomen that caused short-gut syndrome and dependence on total parenteral nutrition (TPN) twelve hours per day. She...

Cite
Zyczynski LE, McHugh JB, Gribbin TE, et al. Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case Rep Oncol Med. 2015;2015:107479doi: 10.1155/2015/107479.
Zyczynski, L. E., McHugh, J. B., Gribbin, T. E., & Schuetze, S. M. (2015). Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case reports in oncological medicine, 2015107479. https://doi.org/10.1155/2015/107479
Zyczynski, Laura E, et al. "Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy." Case reports in oncological medicine vol. 2015 (2015): 107479. doi: https://doi.org/10.1155/2015/107479
Zyczynski LE, McHugh JB, Gribbin TE, Schuetze SM. Alveolar Rhabdomyosarcoma in a 69-Year-Old Woman Receiving Glucagon-Like Peptide-2 Therapy. Case Rep Oncol Med. 2015;2015:107479. doi: 10.1155/2015/107479. Epub 2015 Jul 22. PMID: 26266067; PMCID: PMC4525456.
Copy Download .nbib Format: NLM
The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children.

The West Indian medical journal

Uslu B, Gurbuz F, Temiz F, Yuksel B, Mungan N, Topaloglu AK.
PMID: 26901603
West Indian Med J. 2015 Sep 03;65(1):141-146. doi: 10.7727/wimj.2014.134.

OBJECTIVE: To reveal the possible role of glucagon-like peptide-1 (GLP-1) in newly diagnosed Type 1 diabetic children.METHODS: Twenty-five newly diagnosed children and 22 healthy children were included in the study.RESULTS: In oral glucose tolerance tests, no correlation was observed...

Cite
Uslu B, Gurbuz F, Temiz F, et al. The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children. West Indian Med J. 2015;65(1):141-146doi: 10.7727/wimj.2014.134.
Uslu, B., Gurbuz, F., Temiz, F., Yuksel, B., Mungan, N., & Topaloglu, A. K. (2015). The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children. The West Indian medical journal, 65(1), 141-146. https://doi.org/10.7727/wimj.2014.134
Uslu, B, et al. "The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children." The West Indian medical journal vol. 65,1 (2015): 141-146. doi: https://doi.org/10.7727/wimj.2014.134
Uslu B, Gurbuz F, Temiz F, Yuksel B, Mungan N, Topaloglu AK. The Investigation of Plasma Glucagon-like Peptide-1 Levels in Newly Diagnosed Type 1 Diabetic Children. West Indian Med J. 2015 Sep 03;65(1):141-146. doi: 10.7727/wimj.2014.134. PMID: 26901603.
Copy Download .nbib Format: NLM
Umbilical Cord Derived Mesenchymal Stem Cells Useful in Insulin Production - Another Opportunity in Cell Therapy.

International journal of stem cells

Sarang S, Viswanathan C.
PMID: 27426087
Int J Stem Cells. 2016 May 30;9(1):60-9. doi: 10.15283/ijsc.2016.9.1.60.

BACKGROUND AND OBJECTIVES: Type 1 Diabetes Mellitus (T1DM) is an autoimmune disorder resulting out of T cell mediated destruction of pancreatic beta cells. Immunomodulatory properties of mesenchymal stem cells may help to regenerate beta cells and/or prevent further destruction...

Cite
Sarang S, Viswanathan C. Umbilical Cord Derived Mesenchymal Stem Cells Useful in Insulin Production - Another Opportunity in Cell Therapy. Int J Stem Cells. 2016;9(1):60-9doi: 10.15283/ijsc.2016.9.1.60.
Sarang, S., & Viswanathan, C. (2016). Umbilical Cord Derived Mesenchymal Stem Cells Useful in Insulin Production - Another Opportunity in Cell Therapy. International journal of stem cells, 9(1), 60-9. https://doi.org/10.15283/ijsc.2016.9.1.60
Sarang, Shabari, and Viswanathan, Chandra. "Umbilical Cord Derived Mesenchymal Stem Cells Useful in Insulin Production - Another Opportunity in Cell Therapy." International journal of stem cells vol. 9,1 (2016): 60-9. doi: https://doi.org/10.15283/ijsc.2016.9.1.60
Sarang S, Viswanathan C. Umbilical Cord Derived Mesenchymal Stem Cells Useful in Insulin Production - Another Opportunity in Cell Therapy. Int J Stem Cells. 2016 May 30;9(1):60-9. doi: 10.15283/ijsc.2016.9.1.60. PMID: 27426087; PMCID: PMC4961105.
Copy Download .nbib Format: NLM
Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness.

Nutrition & diabetes

Germain N, Galusca B, Caron-Dorval D, Martin JF, Pujos-Guillot E, Boirie Y, Khalfallah Y, Ling Y, Minnion JS, Bloom SR, Epelbaum J, Estour B.
PMID: 25027794
Nutr Diabetes. 2014 Jul 14;4:e126. doi: 10.1038/nutd.2014.17.

BACKGROUND: Contrasting with obesity, constitutional thinness (CT) is a rare condition of natural low bodyweight. CT exhibits preserved menstruation in females, no biological marker of undernutrition, no eating disorders but a bodyweight gain desire. Anorexigenic hormonal profile with high...

Cite
Germain N, Galusca B, Caron-Dorval D, et al. Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutr Diabetes. 2014;4:e126doi: 10.1038/nutd.2014.17.
Germain, N., Galusca, B., Caron-Dorval, D., Martin, J. F., Pujos-Guillot, E., Boirie, Y., Khalfallah, Y., Ling, Y., Minnion, J. S., Bloom, S. R., Epelbaum, J., & Estour, B. (2014). Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutrition & diabetes, 4e126. https://doi.org/10.1038/nutd.2014.17
Germain, N, et al. "Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness." Nutrition & diabetes vol. 4 (2014): e126. doi: https://doi.org/10.1038/nutd.2014.17
Germain N, Galusca B, Caron-Dorval D, Martin JF, Pujos-Guillot E, Boirie Y, Khalfallah Y, Ling Y, Minnion JS, Bloom SR, Epelbaum J, Estour B. Specific appetite, energetic and metabolomics responses to fat overfeeding in resistant-to-bodyweight-gain constitutional thinness. Nutr Diabetes. 2014 Jul 14;4:e126. doi: 10.1038/nutd.2014.17. PMID: 25027794; PMCID: PMC5189928.
Copy Download .nbib Format: NLM
Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1.

Frontiers in immunology

Zietek T, Rath E.
PMID: 27148273
Front Immunol. 2016 Apr 22;7:154. doi: 10.3389/fimmu.2016.00154. eCollection 2016.

Chronic diseases, such as obesity and diabetes, cardiovascular, and inflammatory bowel diseases (IBD) share common features in their pathology. Metabolic disorders exhibit strong inflammatory underpinnings and vice versa, inflammation is associated with metabolic alterations. Next to cytokines and cellular...

Cite
Zietek T, Rath E. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Front Immunol. 2016;7:154doi: 10.3389/fimmu.2016.00154.
Zietek, T., & Rath, E. (2016). Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Frontiers in immunology, 7154. https://doi.org/10.3389/fimmu.2016.00154
Zietek, Tamara, and Rath, Eva. "Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1." Frontiers in immunology vol. 7 (2016): 154. doi: https://doi.org/10.3389/fimmu.2016.00154
Zietek T, Rath E. Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1. Front Immunol. 2016 Apr 22;7:154. doi: 10.3389/fimmu.2016.00154. eCollection 2016. PMID: 27148273; PMCID: PMC4840214.
Copy Download .nbib Format: NLM
Leptin recruits Creb-regulated transcriptional coactivator 1 to improve hyperglycemia in insulin-deficient diabetes.

Molecular metabolism

Kim GH, Szabo A, King EM, Ayala J, Ayala JE, Altarejos JY.
PMID: 25737949
Mol Metab. 2014 Dec 19;4(3):227-36. doi: 10.1016/j.molmet.2014.12.006. eCollection 2015 Mar.

OBJECTIVE: Leptin alleviates hyperglycemia in rodent models of Type 1 diabetes by activating leptin receptors within the central nervous system. Here we delineate whether non-canonical leptin signaling through the Creb-regulated transcriptional coactivator 1 (Crtc1) contributes to leptin-dependent improvements in...

Cite
Kim GH, Szabo A, King EM, et al. Leptin recruits Creb-regulated transcriptional coactivator 1 to improve hyperglycemia in insulin-deficient diabetes. Mol Metab. 2014;4(3):227-36doi: 10.1016/j.molmet.2014.12.006.
Kim, G. H., Szabo, A., King, E. M., Ayala, J., Ayala, J. E., & Altarejos, J. Y. (2015). Leptin recruits Creb-regulated transcriptional coactivator 1 to improve hyperglycemia in insulin-deficient diabetes. Molecular metabolism, 4(3), 227-36. https://doi.org/10.1016/j.molmet.2014.12.006
Kim, Geun Hyang, et al. "Leptin recruits Creb-regulated transcriptional coactivator 1 to improve hyperglycemia in insulin-deficient diabetes." Molecular metabolism vol. 4,3 (2015): 227-36. doi: https://doi.org/10.1016/j.molmet.2014.12.006
Kim GH, Szabo A, King EM, Ayala J, Ayala JE, Altarejos JY. Leptin recruits Creb-regulated transcriptional coactivator 1 to improve hyperglycemia in insulin-deficient diabetes. Mol Metab. 2014 Dec 19;4(3):227-36. doi: 10.1016/j.molmet.2014.12.006. eCollection 2015 Mar. PMID: 25737949; PMCID: PMC4338314.
Copy Download .nbib Format: NLM
Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated.

Journal of diabetes investigation

Osawa S, Yasuda T, Kaneto H, Shimo N, Yamamoto Y, Kawamori D, Miyatsuka T, Matsuoka TA, Shimomura I.
PMID: 25621140
J Diabetes Investig. 2015 Jan;6(1):105-6. doi: 10.1111/jdi.12251. Epub 2015 Jan 01.

No abstract available.

Cite
Osawa S, Yasuda T, Kaneto H, et al. Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated. J Diabetes Investig. 2015;6(1):105-6doi: 10.1111/jdi.12251.
Osawa, S., Yasuda, T., Kaneto, H., Shimo, N., Yamamoto, Y., Kawamori, D., Miyatsuka, T., Matsuoka, T. A., & Shimomura, I. (2015). Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated. Journal of diabetes investigation, 6(1), 105-6. https://doi.org/10.1111/jdi.12251
Osawa, Saeko, et al. "Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated." Journal of diabetes investigation vol. 6,1 (2015): 105-6. doi: https://doi.org/10.1111/jdi.12251
Osawa S, Yasuda T, Kaneto H, Shimo N, Yamamoto Y, Kawamori D, Miyatsuka T, Matsuoka TA, Shimomura I. Case of aniridia with a heterozygous PAX6 mutation in which the glucagon response to arginine was evaluated. J Diabetes Investig. 2015 Jan;6(1):105-6. doi: 10.1111/jdi.12251. Epub 2015 Jan 01. PMID: 25621140; PMCID: PMC4296710.
Copy Download .nbib Format: NLM
Injectable Coformulations in Diabetology.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Kalra S, Gupta Y.
PMID: 25801349
Diabetes Ther. 2015 Jun;6(2):101-11. doi: 10.1007/s13300-015-0106-2. Epub 2015 Mar 24.

Coformulations are a novel pharmaceutical development in diabetology. They are composed of two medicinal products, both of which maintain their distinct pharmacokinetic and pharmacodynamic properties. Currently available coformulations include combinations of basal and rapid-acting insulin, and basal and glucagon-like...

Cite
Kalra S, Gupta Y. Injectable Coformulations in Diabetology. Diabetes Ther. 2015;6(2):101-11doi: 10.1007/s13300-015-0106-2.
Kalra, S., & Gupta, Y. (2015). Injectable Coformulations in Diabetology. Diabetes therapy : research, treatment and education of diabetes and related disorders, 6(2), 101-11. https://doi.org/10.1007/s13300-015-0106-2
Kalra, Sanjay, and Gupta, Yashdeep. "Injectable Coformulations in Diabetology." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 6,2 (2015): 101-11. doi: https://doi.org/10.1007/s13300-015-0106-2
Kalra S, Gupta Y. Injectable Coformulations in Diabetology. Diabetes Ther. 2015 Jun;6(2):101-11. doi: 10.1007/s13300-015-0106-2. Epub 2015 Mar 24. PMID: 25801349; PMCID: PMC4478180.
Copy Download .nbib Format: NLM
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach.

World journal of diabetes

Johansen OE.
PMID: 26265995
World J Diabetes. 2015 Aug 10;6(9):1092-6. doi: 10.4239/wjd.v6.i9.1092.

In cardiovascular (CV) diabetology a "one-size fits-all" approach needs caution as vasculopathy and CV manifestations in patients with type 2 diabetes (T2D) with short disease duration are different as compared to those with longer duration. This is of relevance...

Cite
Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes. 2015;6(9):1092-6doi: 10.4239/wjd.v6.i9.1092.
Johansen, O. E. (2015). Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World journal of diabetes, 6(9), 1092-6. https://doi.org/10.4239/wjd.v6.i9.1092
Johansen, Odd Erik. "Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach." World journal of diabetes vol. 6,9 (2015): 1092-6. doi: https://doi.org/10.4239/wjd.v6.i9.1092
Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes. 2015 Aug 10;6(9):1092-6. doi: 10.4239/wjd.v6.i9.1092. PMID: 26265995; PMCID: PMC4530322.
Copy Download .nbib Format: NLM
GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass.

Endocrinology, diabetes & metabolism case reports

Guimarães M, Rodrigues P, Pereira SS, Nora M, Gonçalves G, Albrechtsen NW, Hartmann B, Holst JJ, Monteiro MP.
PMID: 26266036
Endocrinol Diabetes Metab Case Rep. 2015;2015:150049. doi: 10.1530/EDM-15-0049. Epub 2015 Jul 15.

UNLABELLED: Post-prandial hypoglycemia is frequently found after bariatric surgery. Although rare, pancreatic neuroendocrine tumors (pNET), which occasionally are mixed hormone secreting, can lead to atypical clinical manifestations, including reactive hypoglycemia. Two years after gastric bypass surgery for the treatment...

Cite
Guimarães M, Rodrigues P, Pereira SS, et al. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol Diabetes Metab Case Rep. 2015;2015:150049doi: 10.1530/EDM-15-0049.
Guimarães, M., Rodrigues, P., Pereira, S. S., Nora, M., Gonçalves, G., Albrechtsen, N. W., Hartmann, B., Holst, J. J., & Monteiro, M. P. (2015). GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinology, diabetes & metabolism case reports, 2015150049. https://doi.org/10.1530/EDM-15-0049
Guimarães, Marta, et al. "GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass." Endocrinology, diabetes & metabolism case reports vol. 2015 (2015): 150049. doi: https://doi.org/10.1530/EDM-15-0049
Guimarães M, Rodrigues P, Pereira SS, Nora M, Gonçalves G, Albrechtsen NW, Hartmann B, Holst JJ, Monteiro MP. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol Diabetes Metab Case Rep. 2015;2015:150049. doi: 10.1530/EDM-15-0049. Epub 2015 Jul 15. PMID: 26266036; PMCID: PMC4530374.
Copy Download .nbib Format: NLM
Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response.

Molecular metabolism

Rojas JM, Matsen ME, Mundinger TO, Morton GJ, Stefanovski D, Bergman RN, Kaiyala KJ, Taborsky GJ, Schwartz MW.
PMID: 26266088
Mol Metab. 2015 Jun 04;4(8):561-8. doi: 10.1016/j.molmet.2015.05.005. eCollection 2015 Aug.

OBJECTIVE: Central administration of ligands for fibroblast growth factor receptors (FGFRs) such as fibroblast growth factor-19 (FGF19) and FGF21 exert glucose-lowering effects in rodent models of obesity and type 2 diabetes (T2D). Conversely, intracerebroventricular (icv) administration of the non-selective...

Cite
Rojas JM, Matsen ME, Mundinger TO, et al. Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response. Mol Metab. 2015;4(8):561-8doi: 10.1016/j.molmet.2015.05.005.
Rojas, J. M., Matsen, M. E., Mundinger, T. O., Morton, G. J., Stefanovski, D., Bergman, R. N., Kaiyala, K. J., Taborsky, G. J., & Schwartz, M. W. (2015). Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response. Molecular metabolism, 4(8), 561-8. https://doi.org/10.1016/j.molmet.2015.05.005
Rojas, Jennifer M, et al. "Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response." Molecular metabolism vol. 4,8 (2015): 561-8. doi: https://doi.org/10.1016/j.molmet.2015.05.005
Rojas JM, Matsen ME, Mundinger TO, Morton GJ, Stefanovski D, Bergman RN, Kaiyala KJ, Taborsky GJ, Schwartz MW. Glucose intolerance induced by blockade of central FGF receptors is linked to an acute stress response. Mol Metab. 2015 Jun 04;4(8):561-8. doi: 10.1016/j.molmet.2015.05.005. eCollection 2015 Aug. PMID: 26266088; PMCID: PMC4529498.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 3591 entries